ProKidney Advances Kidney Disease Treatment
ProKidney updates Phase III strategy for rilparencel, aiming for expedited FDA approval.
ProKidney, a clinical-stage biotech company, has announced
strategic updates to its Phase III development program for rilparencel, a
promising investigational therapy aimed at preserving kidney function in
patients with type 2 diabetes and advanced chronic kidney disease (CKD). The
decision follows an in-depth review by internal and external experts, including
consultations with former FDA officials and seasoned regulatory professionals.
Through this review, ProKidney concluded that under the
Regenerative Medicine Advanced Therapy (RMAT) designation, rilparencel may
qualify for FDA approval through an expedited pathway. The company now believes
that successful completion of the ongoing Phase III REGEN-006 (PROACT 1) trial
could be sufficient for the initial US approval of rilparencel. As a result,
the previously planned Phase III REGEN-016 (PROACT 2) trial is no longer seen
as necessary for initial registration.
This update signals ProKidney’s commitment to addressing the
significant unmet need for effective treatments in patients with
diabetes-related CKD, a condition with considerable clinical and economic
impact. The potential expedited approval could bring relief to patients faster,
positioning rilparencel as a critical therapy in a high-demand market.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion